Shots:

• Sorrento to get access to plasma containing anti-COVID-19 Abs for identifying and produce mAbs with neutralizing activity against SARS-CoV-2. The company expects to commence the P-I study of triple Ab combination therapy in Q3’20
• The focus of the collaboration is to jointly develop Ab cocktail which will act as a protective shield against COVID-19 and potentially block the virus in naïve at-risk populations and infected individuals. The therapy is designed to be resistant to future mutations in the virus
• If approved- each dose of COVI-SHIELD will deliver a cocktail of three Abs which together would recognize three unique regions of the SARS-CoV-2 spike protein and can provide protection for up to 2mos. at a time

Click here to read full press release/ article | Ref: Sorrento Therapeutics | Image: Twitter